VÄSTRA FRÖLUNDA, Sweden--(BUSINESS WIRE)-- In collaboration with Small Bone Innovations (SBi), Artimplant has developed a new product in the Artelon® Spacer range with a similar user-friendly textile design to Artelon® Tissue Reinforcement (ATR). The product, Artelon® CMC Soft, has been granted CE-approval by the certification body Lloyd’s and has thus been granted clearance for marketing in Europe.
The major difference between the old Artelon® CMC Spacer and the new Artelon® CMC Soft is that the size can be adjusted and can thus be adapted to the requirements of each individual patient. Artimplant estimates that Artelon® CMC Soft will gradually replace existing Spacer products for thumb base osteoarthritis in the CMC-joint.
Further information is available at www.artimplant.com. To subscribe to future press releases please go to www.artimplant.com/investors-media/subscribe-to-press-releases.html
Artimplant
Artimplant’s mission is to restore the health of patients by offering medical professionals degradable implants that help the body to heal. Artimplant is a medical device company that restores health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products are made from Artelon®, a biomaterial developed by the Company. Artimplant’s implants are used for the treatment of osteoarthritis and the reinforcement of weakened soft tissue. The Company’s products are sold through licensees and own sales under the Artimplant brand take place through agents and distributors. Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in the Small Cap segment and in the Healthcare sector.
Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company’s business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company’s filings.
This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on March 28 2011 at 10:00am (CET).
This information was brought to you by Cision http://www.cisionwire.com
Contact:
Hans Rosén, CEO phone 46 (0)31-746 56 00, 46 (0)708 58 34 70 hans.rosen@artimplant.com or Lars-Johan Cederbrant, CFO phone 46 (0)31-746 56 54, 46 (0)703 01 68 54 lars-johan.cederbrant@artimplant.com
